Polymorphisms of MMP-1 and MMP-3 and susceptibility to rheumatoid arthritis. A meta-analysis

C Zhang1, L Chen, Y Gu

  • 1Department of Orthopaedic Surgery, The First Affiliated Hospital of Soochow University, No 188 ShiziStreet, 215006, Suzhou, China.

Abstract

Insights

This meta-analysis found no significant link between rheumatoid arthritis (RA) and specific matrix metalloproteinase (MMP) gene polymorphisms (MMP-1 and MMP-3). Further research is needed to understand the role of these MMP gene variations in RA development.

Area of Science:

  • Genetics and Rheumatology
  • Molecular Biology
  • Disease Association Studies

Background:

  • Matrix metalloproteinase (MMP) genes, specifically MMP-1 and MMP-3, possess functional polymorphisms (1607 1G/2G and 1171 5A/6A) that have been hypothesized to contribute to rheumatoid arthritis (RA) development.
  • Previous research suggests a potential role for these MMP gene polymorphisms in the pathogenesis of RA, necessitating further investigation.

Purpose of the Study:

  • To conduct a comprehensive meta-analysis to determine the correlation between rheumatoid arthritis (RA) and the MMP-1 (1607 1G/2G) and MMP-3 (1171 5A/6A) gene polymorphisms.
  • To validate the functional significance of these specific MMP gene polymorphisms in the context of RA risk.

Main Methods:

  • A systematic literature search was performed across multiple databases (PubMed, ISI Web of Knowledge, MEDLINE, Embase, Google Scholar, Chinese Biomedical Literature Database, Wanfang Data) to identify relevant case-control studies.
  • Studies investigating the association between MMP-1-1607 1G/2G and MMP-3-1171 5A/6A polymorphisms and RA risk were included.
  • Statistical analysis involved calculating pooled odds ratios (OR) with 95% confidence intervals (CI) to assess the strength of association.

Main Results:

  • Five articles met the inclusion criteria for the meta-analysis.
  • Neither the MMP-1-1607 1G/2G nor the MMP-3-1171 5A/6A polymorphism showed a statistically significant association with RA risk across all five genetic models.
  • Subgroup analysis for the MMP-3-1171 5A/6A polymorphism in Caucasian and Asian populations also revealed no significant association with RA.

Conclusions:

  • The findings suggest that the investigated MMP-1 and MMP-3 gene polymorphisms (1607 1G/2G and 1171 5A/6A) are not significantly associated with the risk of developing rheumatoid arthritis.
  • These specific MMP gene variations do not appear to be major genetic risk factors for RA based on current evidence.

Related Concept Videos

Genome-wide Association Studies-GWAS01:11

Genome-wide Association Studies-GWAS

Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...
16.9K
Role of Matrix Metalloproteases in Degradation of ECM01:23

Role of Matrix Metalloproteases in Degradation of ECM

Matrix metalloproteases (MMPs) are enzymes involved in the hydrolysis of proteins and glycoproteins of the extracellular matrix. MMPs are essential for the migration and proliferation of cells through the dense matrix network, throughout embryonic development, and throughout morphogenesis. The first MMP activity discovered was a collagenase in a tadpole's tail undergoing metamorphosis. The active collagen deposition and modifications lead to the morphogenesis of tadpoles into the adult...
3.8K
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
127